IPCALAB vs ORCHPHARMA: Stock Comparison

IPCA Laboratories Limited vs Orchid Pharma Limited

Live data: 28 July 2026, 4:08 PM IST • Source: NSE and company filings

IPCA Laboratories Limited is the larger company by market capitalisation. IPCA Laboratories Limited shows a lower P/E, a higher ROE and a higher dividend yield. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of IPCA Laboratories Limited and Orchid Pharma Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, IPCALAB is more favourable on 12 of 13 scored metrics and ORCHPHARMA on 1These counts are context-free and are not an overall rating.

Key Differences

Market Cap
IPCALAB is the larger company
₹44,350 Cr vs ₹5,001 Cr
P/E Ratio
IPCALAB has a lower P/E
39.8x vs 243.46x
P/B Ratio
ORCHPHARMA has a lower P/B
3.88x vs 5.63x
EPS
IPCALAB has higher earnings per share
₹44.95 vs ₹4.01
Dividend Yield
IPCALAB has a higher dividend yield
0.34% vs 0%
Revenue Growth (TTM YoY)
IPCALAB has faster revenue growth
6.2% vs -1.5%
EPS Growth (TTM YoY)
IPCALAB has faster EPS growth
341.6% vs 0%
Qtr Sales Growth
IPCALAB has stronger quarterly sales growth
6.31% vs 0.05%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricIPCALABORCHPHARMA
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricIPCALABORCHPHARMA
Live Price₹1,789₹985.35
Day Change0.64%-0.26%
Volume2.38 L43,875
52-Week High₹1,944.9₹1,119.8
52-Week Low₹1,251.6₹480
Distance from 52W High-8.02%-12.01%

Valuation

MetricIPCALABORCHPHARMA
Market Cap₹44,350 Cr₹5,001 Cr
P/E Ratio39.8x243.46x
P/B Ratio5.63x3.88x
EPS₹44.95₹4.01
Book Value₹317.84₹253.98
Dividend Yield0.34%0%

Growth

MetricIPCALABORCHPHARMA
Revenue Growth (TTM YoY)6.2%-1.5%
EPS Growth (TTM YoY)341.6%0%
Qtr Sales Growth6.31%0.05%
Qtr Profit Growth80.9%4.26%

Profitability & Leverage

MetricIPCALABORCHPHARMA
ROE16%2.12%
ROCE17.3%2.64%
Net Margin11.83%2.51%
Operating Margin20.5%5.07%
Debt to Equity0.1x0.28x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricIPCALABORCHPHARMA
Promoter Holding44.72%69.84%
FII Holding10.73% 0.1 pp0.81% 0.06 pp
DII Holding37.37% 0.08 pp20.75% 0.5 pp
Public Holding7.18% 0.02 pp8.61% 0.44 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: IPCA Laboratories Limited and Orchid Pharma Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.